EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Amentoflavone, a Preferentially TGF‐β Receptor 1 Inhibitor, Alleviates Cardiac Remodeling and Dysfunction Through Modulating the TGF‐β /Smad and MAPK Signaling Pathways

Jiangjiao Wu, Chengcheng Zhao, Xiaoping Li, Xinyi Guo, Wenjie Tan, Lu Zhou, Ye Zhang, Jianli Zhang, Shuo Zheng, Chunyu Zeng, Gengze Wu iD

Phytotherapy Research · 2026

DOI: 10.1002/ptr.70248 ↗

At a glance

Journal article in Phytotherapy Research, 2026. Written by Jiangjiao Wu and 10 co-authors. Institution: Department of Cardiology, Daping Hospital, The Third Military Medical University (Army Medical University), Chongqing, China. Major MEDLINE topics: Ventricular Remodeling, Biflavonoids, Transforming Growth Factor beta, MAP Kinase Signaling System. Cited 1 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Natural Science Foundation of China, Natural Science Foundation of Chongqing Municipality, National Key R&D Program of China.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Chronic cardiac stress induces cardiac hypertrophy and fibrosis, thereby promoting pathological heart remodeling, which is the core pathological process of heart failure. Amentoflavone (AMF) has beneficial therapeutic effects against several cardiovascular diseases; however, its role and underlying mechanisms in pathological cardiac remodeling remain unclear. Here, we investigated the protective role of AMF against pathological cardiac remodeling in transverse aortic constriction (TAC)‐induced overloaded hearts. Mice with pressure overload caused by TAC were treated with AMF, and the effects of AMF on cardiac function, cardiac hypertrophy, and fibrosis were analyzed. RNA‐seq, molecular docking, surface plasmon resonance (SPR), and co‐IP were used to identify the downstream targets of AMF. Angiotensin II (Ang II) and transforming growth factor beta 1 (TGF‐β1) were used to characterize the role of AMF and its downstream targets in cardiac hypertrophy and fibrosis in vitro. Sustained AMF administration significantly suppressed TAC‐induced cardiac remodeling. Compared with those in TAC model mice, the heart/body weight ratio, cardiomyocyte cross‐sectional area, and hypertrophic molecular markers were significantly lower in AMF‐treated TAC model mice. Moreover, TAC‐induced myofibroblast generation and extracellular matrix deposition were effectively reversed following AMF administration. Similar results were obtained after AMF treatment for cardiomyocyte hypertrophy and cardiac fibrosis in vitro. Mechanistically, by directly binding to TGF‐β receptor 1, AMF blocked the regulatory effect of TGF‐β1 and inhibited the TGF‐β/Smad and MAPK signaling pathways. These results suggest that AMF, through binding to TGF‐β receptor 1, may be a promising therapeutic option for pathological cardiac remodeling.

Subjects

MeSH terms (MEDLINE)

Ventricular RemodelingBiflavonoidsTransforming Growth Factor betaMAP Kinase Signaling SystemReceptor, Transforming Growth Factor-beta Type IAnimalsMaleMiceCardiomegalyMice, Inbred C57BLFibrosisTransforming Growth Factor beta1Signal TransductionSmad ProteinsMyocytes, CardiacMolecular Docking SimulationAngiotensin IIMyocardium

Author keywords

TGF‐β signalingamentoflavonecardiac fibrosiscardiac hypertrophycardiac remodelingheart failure

Substances

BiflavonoidsamentoflavoneTransforming Growth Factor beta1Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type ISmad ProteinsAngiotensin II

Authors and institutions

  • Department of Cardiology, Daping Hospital, The Third Military Medical University (Army Medical University), Chongqing, China.
  • Key Laboratory of Geriatric Cardiovascular and Cerebrovascular Disease, Ministry of Education, Chongqing, China.
  • Chongqing Key Laboratory for Hypertension Research, Chongqing Cardiovascular Clinical Research Center, Chongqing Institute of Cardiology, Chongqing, China.
  • College of Bioengineering, Chongqing University, Chongqing, China.
  • Department of Cardiology, 921 Hospital of Joint Logistics Support Force People's Liberation Army of China (The Second Affiliated Hospital of Hunan Normal University), Changsha, China.
  • College of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China.

ORCID profiles: Gengze Wu

Funding

  • National Natural Science Foundation of China
  • Natural Science Foundation of Chongqing Municipality
  • National Key R&D Program of China
  • National Talent Support Project of Daping Hospital
  • National Key Research and Development Program of China

Cite

APA

Wu, J., Zhao, C., Li, X., Guo, X., Tan, W., Zhou, L., Zhang, Y., Zhang, J., Zheng, S., Zeng, C., & Wu, G. (2026). Amentoflavone, a Preferentially TGF‐β Receptor 1 Inhibitor, Alleviates Cardiac Remodeling and Dysfunction Through Modulating the TGF‐β /Smad and MAPK Signaling Pathways. Phytotherapy Research. https://doi.org/10.1002/ptr.70248

Vancouver

Wu J, Zhao C, Li X, Guo X, Tan W, Zhou L, et al. Amentoflavone, a Preferentially TGF‐β Receptor 1 Inhibitor, Alleviates Cardiac Remodeling and Dysfunction Through Modulating the TGF‐β /Smad and MAPK Signaling Pathways. Phytotherapy Research. 2026. doi:10.1002/ptr.70248

BibTeX
@article{Wu2026,
  author = {Wu, Jiangjiao and Zhao, Chengcheng and Li, Xiaoping and Guo, Xinyi and Tan, Wenjie and Zhou, Lu and Zhang, Ye and Zhang, Jianli and Zheng, Shuo and Zeng, Chunyu and Wu, Gengze},
  title = {Amentoflavone, a Preferentially TGF‐β Receptor 1 Inhibitor, Alleviates Cardiac Remodeling and Dysfunction Through Modulating the TGF‐β /Smad and MAPK Signaling Pathways},
  journal = {Phytotherapy Research},
  year = {2026},
  doi = {10.1002/ptr.70248}
}
Start for free →